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Background: B-type natriuretic peptide (BNP) has been used recently as a biological marker in patients with
coronary artery disease (CAD) with ST-elevation, as well as without ST-elevation. BNP is able to predict
systolic dysfunction, adding new prognostic information to existing traditional markers. However is not
known if there is a relation between the quantity of BNP levels and the severity of coronary artery disease.
Methods: This study compared B-type natriuretic peptide (BNP) levels in patients with stable angina (SA) and
acute coronary syndromes (ACS) without ST-elevation in relation to angiographic lesions using TIMI and
Gensini Scores. We studied 282 patients with CAD without ST elevation and preserved systolic function. BNP
samples were measured in all recruited patients within 24 hours of hospitalization.
Results: BNP valueswere progressively increased in relation to the severity of diagnosis: SA (52.6±49.4 pg/mL )UA
(243.3±212 pg/mL) NSTE-ACS (421.7±334 pg/mL) (pb0.0001 and pb0.007 respectively). No statistically
signiﬁcant difference was observed between patients with SA and controls (21.2±6.8 pg/mL). The analysis of
BNP levels in relation to the number of involved vessels demonstrated signiﬁcantly increased levels in patients with
multivessel disease compared to patients with 1 or 2 vessel disease (1–86.2±46.3 pg/mL; 2–127±297 pg/mL;
3–295±318 pg/mL; 4–297±347 pg/mL pb0.001 and pb0.003). Evaluation of BNP using Gensini Score showed a
strong relation between BNP and coronary disease extension (r=0.38 pb0.0001).This trend was maintained in all
CAD groups (SA=r 0.54; UA r=0.36 NSTE-ACS r=0.28).
Conclusions:Circulating BNP levels appear elevated in ACSwith diffuse coronary involvement, even in the absence of
systolic dysfunction. BNP is also associated with multi-vessel disease and the extension of coronary disease.
© 2011 Elsevier B.V. All rights reserved.1. Introduction
B-type Natriuretic Peptide (BNP) is a peptide consisting of 32
aminoacids produced by the myocytes as a pro-hormone. It is released
in response to ventricular dilatation and pressure overload , in its active
form after peptidase degradation, into the cardiovascular system [1].
BNP levels are increased after myocardial infarction and high levels are
related to an increased risk of adverse events [2]. Recently it has been
demonstrated that BNP and N-terminal pro-B-type natriuretic peptide
(NT pro-BNP) also provide predictive information on acute coronary
syndromes (ACS) , and they appear related to the severity of CAD in
patients affected with ACS [3,4].icine and Metabolic Diseases,
3100 Siena, Italy. Tel.: +39
l rights reserved.Coronary syndromes without ST elevation are a heterogeneous
disorder ranging from stable angina (SA)without evidence of myocardial
necrosis, tomyocardial infarction (NSTE-ACS). Because of different clinical
presentations, coronary syndromes without ST elevation encompass a
wide range of events and have different prognostic values in relation to
the type of plaque lesions and the diffusion of coronary atherosclerosis.
The risk assessment, based on clinical history and examination,
electrocardiographic (ECG) characteristics, and markers of myocardial
damage, still remains relatively inaccurate [5]. The risks of subsequent
death and/or recurrent ischemic events also vary widely, depending on
the presence of myocardial ischemic areas, irreversible myocyte injury,
the hemodynamic consequences of ischemia and the extent of coronary
atherosclerosis. Several studies in ACS patients demonstrated a strong
association between increased BNP levels and poor clinical outcome;
however, the underlying mechanisms responsible for this association are
not well clariﬁed: BNP and pro-BNP could be indicators for multivessel
disease, poor TIMI ﬂow, as well as markers of coronary disease extension
[4,6,7]. To support this hypothesis, we compared BNP levels in patients
130 A. Palazzuoli et al. / Regulatory Peptides 167 (2011) 129–133with stable angina and ACS in relation to angiographic lesions, vessel
narrowing, and the extension of coronary disease, using TIMI and Gensini
Scores.
2. Materials and methods
2.1. Study population
The starting group consisted of 397 patients, 54were excluded for left
ventricular (LV) systolic dysfunction at echocardiographic examination,
40 for previous myocardial infarction or revascularization, and 21 for
associated signiﬁcant valvular disease. The study was performed on the
remaining 282 subjects (154 males, 138 females) with the main
complaint of chest pain and no-ST elevation, who underwent coronary
artery angiography in our Department from May 2006 to October 2008.
Patients were divided in four groups: Group 0 (controls, n=32) was
submitted to angiographic examination for atypical chest pain, the
angiography revealedhealthy coronary vessels, Group I (stable angina SA,
n=71), Group II (unstable angina UA, n=83), and Group III (non S-T
elevation myocardial infarction NSTE-ACS, n=96).
SA was deﬁned as typical angina that is precipitated by exertion or
emotional stress, it is associated with an electrocardiographic (ECG)
horizontal or downsloping S-T segment depression of more than
1.5 mm during exercise. These symptoms were combined with S-T
segment depression and changes in biochemical biomarkers of
myocardial necrosis (myoglobin CK-MB and Troponin TnT). SA was
also diagnosedwhen the complete diagnostic protocol was performed
in the Chest Pain Unit and did not demonstrate myocardial necrosis or
ischemia. Patients who showed increased CKMB and/or troponin-I
levels after the performance of percutaneous transluminal coronary
angioplasty (PCI) were not considered to have acute myocardial
infarction (AMI).
UA is deﬁned by ECG ST-segment depression or prominent T-wave
inversion with negative biomarkers of necrosis in an appropriate
clinical setting (chest discomfort or angina equivalent). Unstable
angina was diagnosed when, in the absence of the above mentioned
troponin-I or CKMB changes, suggestive chest pain lasting longer than
20 min was associated with either ST-segment depression (≥0.1 mV)
or T-wave inversion in the ECG, pre-discharge ischemic stress test, or
signiﬁcant coronary artery disease in an angiogram [8].
NSTE-ACS was diagnosed when an elevation of troponin-I levels
(N1.0 ng/mL in any sample during the ﬁrst 9 hours post-admission)
and/or a typical CKMB curve occurred, with or without ST/T changes
in the ECG, in the absence of any other demonstrable cause for the
chest pain [9]. Patients were evaluated prior to blood sampling to
determine their heart failure status according to the New York Heart
Association. All recruited patients underwent echocardiographic
examination (Hewlett-Packard, 5500 Sonos Philips) to evaluate
modiﬁcations in parietal kinesis, left ventricular morphology and
systolic function [10]. Blood samples for BNP were performed within
24 hours (median 14±6) of hospital admission. Sixty milliliters of
blood were taken from a peripheral veins and distributed in tubes for
BNP detection. The study was approved by the Local Human Scientiﬁc
Committee. All reported investigations have been carried out in
accordance with the principles of the Declaration of Helsinki and
written informed consent was obtained from all patients. Within the
ﬁrst 3 days of hospital admission, left cardiac catheterization and
selective coronary angiography were performed.
2.2. Exclusion criteria
Patientswith ahistory ofmyocardial infarction, valvular disease, acute
or chronic heart failure, cardiomyopathy, systolic dysfunction, ejection
fraction b50%, renal liver and neoplastic diseaseswere excluded. Patients
with ST-elevations on the admission-electrocardiogram were excluded.
Patients were also excludedwhen the evolution of the electrocardiogramshowed the development of a new left bundle branch block or new Q-
waves. Other exclusion criteria were known or suspected infectious or
inﬂammatory conditions and scheduled revascularization procedures.
2.3. Treatment protocol
All patients underwent standard therapy with aspirin, nitrates,
calcium-antagonists or beta-blockers, heparin or low molecular
weight heparin. Patients with NSTE-ACS were also treated with
glycoprotein IIb/IIIa inhibitors (Tiroﬁban) or clopidrogrel.
2.4. Laboratory assays
Creatine kinase levelswere analyzed by a standard technique and its
MB fractions by electrophoresis. Myoglobin and TnT were assayed by
automate enzyme immunoassay. The levels of TnTwere determined by
a third-generation assay on an Elecsys (Roche Diagnostics, Basel,
Switzerland), with the detection limit at 0.01 μg/L and a total coefﬁcient
of variance (CV) of 8% at 0.05 μg/L and 4.1% to 6.0% between 0.1 and
11 μg/L. An excess of 0.05 μg/l for TnT and 50 μg/L for myoglobin were
suggestive for signiﬁcant myocardial damage. Plasma BNP was
immediately analysed on the same EDTA-anti-coagulated blood sample
collected on admission for CK-MB and troponin-I, using the quantitative
immunoﬂuorescence assay manufactured by Biosite (San Diego, CA,
USA). The analytic sensitivity of the assay is b5 pg/mL and the upper
normal limit is considered to be 100 pg/mL. Plasma CK-MB mass was
measured by immunoﬂuorescence assay manufactured by Dade-
Behring (Marburg, Germany). The analytic sensitivity of the assay is
0.6 ng/mL and the upper normal limit is considered to be 5.0 ng/mL.
Plasma troponin-I was measured by immunoﬂuorescence assay
manufactured by Dade-Behring. The analytic sensitivity of the assay is
0.1 ng/mL and the upper normal limit for the diagnosis of AMI was
considered to be 1.0 ng/mL.
2.5. Angiographic analysis
All coronary angiograms were evaluated at the TIMI angiographic
score laboratory byphysicianswhowere blinded to the patient's clinical
or BNP status. Coronary stenosis was quantiﬁed using validated
quantitative coronary angiography. Assessment of epicardial coronary
ﬂow was done using the TIMI ﬂow grade according to previously
describedmethods [11]. The Gensini score (GS) was used in the present
study to assess the burden of coronary arteriosclerosis [12]. The GS
system yields a qualitative and quantitative evaluation of the coronary
angiogram; it grades the narrowing of the lumen of the coronary artery
as 1 for≤25% narrowing, 2 for 26–50% narrowing, 4 for 51–75%
narrowing, 8 for 76–90% narrowing, 16 for 91–99% narrowing, and 32
for total occlusion. This primary score ismultiplied by a factor that takes
into account the importance of the position of the lesion in the coronary
arterial tree (5 for the leftmain coronary artery, 2.5 for the proximal left
anterior descending artery or proximal left circumﬂex artery and 1.5 for
themid-region, 1 for the distal left anterior descending artery, and 1 for
the mid-distal region of the left circumﬂex artery or right coronary
artery). In this study, the GS was expressed as the sum of the scores for
all three coronary arteries in order to evaluate the entire extent of CAD.
The grades of luminal narrowing were determined by the consensus
opinion of two experienced interventional cardiologists.
2.6. Statistical analysis
The statistical analysis was performed using the SPSS software for
Windows, version 9.0.1 (SPSS, Inc., Chicago, IL). Summary statistics for
continuous variables were recorded as the mean±SD, and the
categorical data was summarized as frequencies and percentages.
Multiple group comparisons were performed using Kruskal–Wallis
test followed by Mann–Whitney U test when signiﬁcant differences
Fig. 1. BNP levels in Controls, Stable angina (SA), Unstable Angina ( UA), andMyocardial
Infarction (NSTEMI).
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calculated according to Spearman-Rho. Univariate logistic regression
analysis was performed with the presence of CAD as the dependent
variable and BNP levels, age, current smoking, cholesterol levels,
diabetes, hypertension, body mass index (BMI) and ST segment
deviation N1 mm, as independent variables, Odds Ratio (OR) is
presented with 95% conﬁdence intervals. All numeric data are
presented as the mean±SD, and a p value of less than 0.05 was
considered statistically signiﬁcant.
3. Results
3.1. BNP and clinical presentation
All of the remaining 282 patients had BNP levels and angiographic
data: clinical characteristics and associated risk factor are reported in
Table 1. BNP levels were similar in controls and the SA group (32.1±
23 pg/mL vs 55.4±63 pg/mL NS) but it revealed progressively
increasing values in relation to the diagnosis: BNP levels were
signiﬁcantly different between the SA Group and the UA Group
(237.1±261 pg/mL; pb0.01) as well as between the SA Group and
the NSTE-ACS Group ( 340.2±283 pg/mL; pb0.001). Even in ACS,
BNP showed different values in the UA Group compared to the NSTE-
ACS Group (pb0.007) (Fig. 1). BNPN80 pg/mL was recruited in 176
patients, most of whom had ACS: 21 had SA (12%), 71 had UA (42%),
and 81 had NSTE-ACS (46%). Multi-vessel disease was revealed more
frequently in patients with BNP N80 pg/mL (Table 2).
3.2. BNP and coronary vessel involvement
BNP was strictly related to the extent of coronary disease
measured with traditional methods: signiﬁcant progressive differ-
ences were assessed between the 1-vessel Group, the 2-vessel and
3–4-vessel Group (1-vessel 89.2±47.3; 2-vessels 221,8±182,2;
3–4-vessels 295.8±264.5 pg/mL, pb0.001). A similar signiﬁcant
trend was found between the 2-vessel Group and the 3-vessel
Group (pb0.005), but not signiﬁcant difference was detected
between the 3-vessel and 4-vessel Group (297.2±247 pg/mL NS)
(Fig. 2). When the measurement was limited to the 1-vessel group
(n=44), we observed a signiﬁcantly higher BNP in patients with
left anterior descending artery (LAD) involvement than in patients
with other coronary districts involvement (121,4±56,5 vs 78,6±
64,2 pg/mL, pb0.05).
The analysis of the Gensini Score (GS) demonstrated a strong
correlation between coronary artery disease extension and BNP levels
(r=0.40, pb0.0001) (Fig. 3). This trend was maintained in all CAD
Groups: SA GS 29.9±20.5 (r=0.55, pb0.0001); UA GS 42±20
(r=0.36, pb0.001); NSTE-ACS GS 46.4±17.2 (r=0.28, pb0.05).
3.3. BNP and risk factors
We assessed the association of BNP levels with established
cardiovascular risk factors, including hypercholesterolemia, arterialTable 1
Clinical characteristics and risk factors associated in all group studied.
Stable angina Unstable angina NSTEMI
Number 71 83 96
Sex (m/f) 40/31 43/40 58/38
Diabetes (n) 17 40 42
Hypertension (n) 26 43 44
Smoking (n) 10 9 13
Dyslipidemia (n) 18 30 31
S-T deviation 8 55 72
BNP (pg/ml) 52.6±49.4 243.3±212 421.7±334hypertension, smoking, diabetes, and BMI. Notably, BNP was
positively correlated to hypercholesterolemia (r=0.22, pb0.01) and
diabetes (r=0.48, pb0.001). But there was no correlation with Body
Mass Index (BMI), smoking, hypertension and gender. Univariate
analysis showed that BNP levels were independently and positively
associated with the presence of CAD (OR=15.7, pb0.001); diabetes
and ST deviation were associated with CAD ( OR 2.17, pb0.05 and OR
8.35, pb0.01 respectively); age were weakly associated with CAD (OR
1.32, pb0.05). However smoking, hypertension, and BMI did not show
any association with the disease (Table 3).4. Discussion
Many studies have shown that the elevation of BNP levels, as well
as NT-proBNP levels, obtained after the acute phase in patients with a
broad range of ACS independently predicts mortality. However, in
most of the reports, authors did not distinguish between subjects with
low ejection fraction and LV enlargement [3,4,13]. Because of its
release in response to increased ventricular chamber pressure or wall
tension, in ACS patients with decreased LV ejection fraction, elevated
BNP levels reﬂect a high degree of myocardial dysfunction, with a
higher risk of death and congestive heart failure.
The main ﬁnding of this study is that BNP levels are related not
only to LV dysfunction but also to the severity of coronary
atherosclerosis: patients with multi-vessel disease showed higher
BNP levels than subjects with only one or two vessel involvement.Table 2
Clinical characteristics and associated risk factors in patients with BNPb80 andN80 pg/ml.
BNP b80 BNP N80
Age (yrs) 68.6±6.9 72.5±8.1
Hypertension (%) 45.3 54.7
Diabetes (%) 41.2 58.8
Smoking (%) 70.7 29.3
Dyslipidemia (%) 49.0 51.0
SA 57.9 11.9
UA 29.9 42.1
NSTEMI 12.2 46
Multi-vessel disease (%) 28.7 71.3
Fig. 2. BNP measurement in patients with mono-, bi- and multi-vessels disease. BNP
levels progressively increase in patients with more diffuse coronary atherosclerosis.
Table 3
Association of presence of CADwith BNP levels and traditional risk factors: BNP appears
the most powerful indicator of CAD.
Variable Pearson's correlation Signiﬁcance
Age N70 yrs 0.06 ns
Hypertension 0.06 ns
Diabetes 0.09 ns
Dyslipidemia 0.07 ns
Smoking 0.08 ns
CAD history 0.18 b0.01
ST deviationN2 mm 0.46 b0.0001
Multi vessel disease 0.20 b0.01
BNP N80 pg/ml 0.62 b0.0001
Gensini scoreN20 0.36 b0.0001
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groups. Elevation of BNP levels appears strictly related to coronary
artery disease. Indeed, none of the patients had LV systolic
dysfunction and signs or symptoms of heart failure. Our results are
in accordance with those of Sadanandan et al showing a correlation
between TIMI ﬂow, thigh of culprit stenosis and BNP levels [14].
However, with respect to the cited study, our sample was character-
ized by the absence of left ventricular dysfunction and enlargement
which are the main factors responsible for BNP increase [15,16].
Again, we demonstrated that BNP threshold of 80 pg/ml appears able
to predict the extension of coronary disease independently from LV
systolic dysfunction and enlargement. The same value has been
previously recognized as cutoff for mortality and risk for adverse
events in patients with ACS [3,4,14].
In a previous report, we conﬁrmed this trend showing a direct
correlation between BNP levels and prognosis, even in patients with
preserved systolic function [17]. In this line, Weber et al. demon-Fig. 3. Correlation between BNP and Gensini score in patients with CAD.strated a close correlation between NT-proBNP and disease severity in
patients with stable angina [18]. In contrast with the above data, the
PEACE Trial showed a strong association between cardiovascular
mortality, heart failure and stroke, but not with myocardial infarction,
however in this study there was no coronary angiography performed
[19].
The exact mechanisms of natriuretic peptides rise in coronary
disease are not completely understood. Ischemia may constitute an
independent stimulus for BNP release towards a transient decrease of
systolic function and compliance, reﬂecting not only the impairment
in left ventricular function, but also the severity of the ischemic insult
[20]. Alternatively, BNP secretion may be due to the augmented
regional wall stretch which occurs during ischemic attacks even in the
absence of pump dysfunction inducing the neurohormonal activation
[21]. The detection of BNP gene expression in ischemic and infarcted
regions together with BNP receptor recruitment in coronary plaques
could explain a novel mechanism of BNP induction [23,24]. The strong
correlation between the Gensini Score and BNP levels extend previous
ﬁndings demonstrating that a further stimulus for BNP increase could
be the severity and diffusion of coronary plaques that, consistent with
this observation, lead to a worsening of the ischemic myocardial area
[21,22]. All together these data could explain the mechanisms linking
BNP to an adverse outcome in CAD: it represents a marker of coronary
disease severity and is related to the presence of plaques diffusion and
narrowing. For the above mentioned reasons BNP should be
considered as an indicator of regional ischemia and as a predictor
for adverse events in patients with chest pain [25,26].
5. Study limitations
The present study suffers from several limitations, the major one is
the small sample size. However our sample was carefully deﬁned and
selected on the basis of echocardiographic and clinical criteria. Our
results may have been partially inﬂuenced by a diastolic dysfunction
that was not reported in all patients. Age and sex could have
inﬂuenced the ﬁndings even if the population studied had similar
demographic characteristics in all groups. We did not compare BNP
levels to other biomarkers of myocardial injury such as Troponin, high
sensitive CRP or cytokine levels. At last, the study was a retrospective
analysis: the results should be conﬁrmed in a prospective study with a
larger population.
6. Conclusions
BNP represents a biomarker for left ventricular dysfunction and
enlargement as well as for myocardial ischemia. It appears able to give
additional prognostic information to existing traditional biomarkers
(i.e. troponin and C-reactive protein). BNP is a candidate for entry into
the setting of principal risk scores. Our ﬁndings indicate that the level
of BNPmay reﬂect the extent or severity of ischemic insult even when
irreversible injury and systolic dysfunction have not occurred.
133A. Palazzuoli et al. / Regulatory Peptides 167 (2011) 129–133Acknowledgement
We are grateful to Inverness Medical for the supply of the BNP
laboratory kit. We thank Dr. Nancy Saymour for the technical
assistance and for the help in revising the manuscript.
References
[1] Levin ER, Gardner DG, Samson WK. Natriuretic peptides. [Review]. N Engl J Med
1998;339:321–8.
[2] Arakawa N, Nakamura M, Aoki H, Hiramori K. Plasma brain natriuretic peptide
concentrations predict survival after acute myocardial infarction. J Am Coll Cardiol
1996;27:1656–61.
[3] de Lemos JA, Morrow DA, Bentley JH, et al. The prognostic value of B-type
natriuretic peptide in patients with acute coronary syndromes. N Engl J Med
2001;345:1014–21.
[4] Morrow DA, De Lemos JA, Sabatine MS, et al. Evalutation of B-type natriuretic
peptide for risk assessment in unstable angina/non-ST elevation myocardial
infarction. J Am Coll Cardiol 2003;41:1264–72.
[5] Antman EM, Cohen M, Bernink PJ, et al. The TIMI risk score for unstable angina/
non ST elevation MI: a method for prognostication and therapeutic decision
making. JAMA 2000;284:835–42.
[6] Galvani M, Ottani F, Oltrona L, et al. N-terminal pro-brain natriuretic peptide on
admission has prognostic value across the whole spectrum of acute coronary
syndromes. Circulation 2004;13(110):128–34.
[7] Bazzino O, Fuselli JJ, Botto F, et al. Relative value of N-terminal probrain natriuretic
peptide, TIMI risk score, ACC/AHA prognostic classiﬁcation and other risk markers
in patients with non-ST elevation coronary syndromes. Eur Heart J 2004;25:
859–66.
[8] ACC/AHA 2007Guidelines for theManagement of PatientsWithUnstable Angina/Non–
ST-Elevation Myocardial Infarction A Report of the American College of Cardiology/
American Heart Association Task Force on Practice Guidelines (Writing Committee to
Revise the2002Guidelines for theManagementof PatientsWithUnstableAngina/Non–
ST-Elevation Myocardial Infarction) Developed in Collaboration with the American
College of Emergency Physicians, the Society for Cardiovascular Angiography and
Interventions, and the Society of Thoracic Surgeons Endorsed by the American
Association of Cardiovascular and Pulmonary Rehabilitation and the Society for
Academic Emergency Medicine. J Am Coll Cardiol 2007;50:e1–e157.
[9] Alpert JS, Thygesen K, Antman E, Bassand JP. Myocardial infarction redeﬁned- a
consensus document of the Joint European Society of cardiology/American College
of Cardiology Committee for the redeﬁnition of myocardial infarction. J Am Coll
Cardiol 2000;36:959–69.
[10] Schiller NB, Shah PN, CrawfordM, et al. Recommendations for quantiﬁcation of the
left ventricle by two-dimensional echocardiography. J Am Soc Echocardiogr
1989;2:358–67.[11] Gibson CM, Ryan KA, Kelley M, et al. Methodologic drift in the assessment of TIMI
grade 3 ﬂow and its implications with respect to the reporting of angiographic
trial results. The TIMI Study Group. Am Heart J 1999;137:1179–84.
[12] Gensini GG. A more meaningful scoring system for determining the severity of
coronary heart disease. Am J Cardiol 1983;51:606.
[13] Omland T, Persson A, Ng L, et al. N-terminal pro-B-type natriuretic peptide and
long-term mortality in acute coronary syndromes. Circulation 2002;106:2913–8.
[14] Sadanandan S, Cannon CP, Chekuri K, et al. Association of elevated B-type
natriuretic peptide levels with angiographic ﬁndings among patients with
unstable angina and non-ST-segment elevation myocardial infarction. J Am Coll
Cardiol 2004;44:564–8.
[15] Sabatine MS, Morrow DA, de Lemos JA, et al. Multimarker approach to risk
stratiﬁcation in non-ST elevation acute coronary syndromes. Circulation
2002;105:1760–3.
[16] OmlandT, AakvaagA, BonarjeeVV, et al. Plasmabrainnatriuretic peptide as an indicator
of left ventricular systolic function and long-term survival after acute myocardial
infarction: comparison with plasma atrial natriuretic peptide and N-terminal proatrial
natriuretic peptide. Circulation 1996;93:1963–9.
[17] Palazzuoli A, Deckers J, Calabrò A, et al. Brain Natriuretic Peptide and Other Risk
Markers for Outcome Assessment in Patients With Non–ST-Elevation Coronary
Syndromes and Preserved Systolic Function. Am J Cardiol 2006;98:1322–8.
[18] Weber M, Dill T, Arnold R, Rau M, Ekinci O, et al. N-terminal B-type natriuretic
peptide predicts extent of coronary artery disease and ischemia in patients with
stable angina pectoris. Am Heart J 2004;148:612–20.
[19] OmlandT, SabatineMS, Jablonski KA, RiceMM,Hsia J, et al. Prognostic value ofB-Type
natriuretic peptides in patients with stable coronary artery disease. J Am Coll Cardiol
2007;50:205–14.
[20] Marumoto K, Hamada M, Hiwada K. Increased secretion of atrial and brain
natriuretic peptides during acute myocardial ischaemia induced by dynamic
exercise in patients with angina pectoris. Clin Sci (Colch) 1995;88:551–6.
[21] Staub D, Nusbaumer C, Zellweger MJ, et al. Use of B-type natriuretic peptide in the
detection of myocardial ischemia. Am Heart J 2006;151:1223–30.
[22] Burley DS, Hamid SA, Baxter GF. Cardioprotective action of peptide hormones in
myocardial ischemia. Heart Fail Rev 2007;12:279–91.
[23] Ndrepepa G, Braun S, Shomig A, Kastrati A. Accuracy of N-terminal Pro-brain
Natriuretic Peptide predict mortality in various subset of patients with coronary
artery disease. Am J Cardiol 2007;100:575–8.
[24] Barbato E, Rubattu S, Bartunek J, Berni A, Sarno G, et al. Human coronary
atherosclerosis modulates cardiac natriuretic peptide release. Atherosclerosis
2009;206(1):258–64.
[25] Bassan R, Potsch A, Maisel A, Tura B, Villacorta H, Nogueira MV, Campos A, Gamarski
R, Masetto AC, MoutinhoMA. B-type natriuretic peptide: a novel early bloodmarker
of acute myocardial infarction in patients with chest pain and no ST-segment
elevation. Eur Heart J 2005;26:234–40.
[26] Kwan G, Isakson SA, Beede J, Clopton P, Maisel A, et al. Short-term serial sampling
of natriuretic peptides in patients presenting with chest pain. J Am Coll Cardiol
2007;49:1186–92.
